美国默克促排卵药Elonva(corifollitropin alfa注射剂)已通过欧盟批准,该药与GnRH拮抗剂联用可对患者进行控制性促排卵(COS)。它主要用于那些采用辅助生殖技术(ART)生育的妇女,促进其卵泡发育。
随着Elonva获得欧盟批准,默克将可以在所有欧盟成员国推出这种产品,并采用统一标签
默克促排卵药Elonva

试管婴儿新技术ELONVA给怕针妇女带来福音
新西兰先驱报报道,新西兰本月推出试管婴儿治疗新技术ELONVA,注射一次ELONVA可代替常规治疗的七个每天注射,ELONVA的推出给惧怕针管注射的女士带来了福音。奥克兰生育专家Leigh Gray便是其中一例,由于ELONVA的应用,使她成功怀孕,日前试管婴儿女儿雏菊已14个月大。
近日,旨在了解女性IVF治疗的一项研究中,数据表明29%的女性对注射极其或非常紧张。常规的卵泡刺激素RFSH需要七个注射日,ELONVA作为首个持续卵泡兴奋剂生育治疗,能够启动和维持多个卵泡生长整整一个星期而只需单次皮下注射推荐剂量便可取代七个注射日的RFSH。注射次数的减少很大层面有助于减轻许多妇女身体,心理和情绪上承受的负担。
Leigh Gray有生育念头时已37岁,自然生育无望的她尝试IVF治疗。然而,Leigh Gray讨厌甚至说恐惧针管注射,此前他们私下支付进行了一项体外受精治疗,也正由于Leigh Gray太害怕针管注射了,而使得第一个胚胎着床之后没有生长下来,Leigh Gray回忆说“整个过程我都吓坏了。”当同为奥克兰生育专家的 Leigh Gray同事的伯兹奥尔.玛丽正为ELONVA找寻实验者时,Leigh Gray接受了这次测试,而事实也证明ELONVA适合她。在ELONVA的助航下,夫妻俩在等了一个月将他们初次试试管婴儿治疗冷冻的一个胚胎,解冻并植入Leigh Gray体内。这一次Leigh Gray怀孕了,现在女儿雏菊已14个月大。
博士伯兹奥尔说:“我们可以通过一些创新来带走风险。人们讨厌试管婴儿注射这部分,通过ELONVA的新试管婴儿技术创新,其可用性为帮助妇女减轻接受试管婴儿治疗痛楚迈出了积极一步。”
See related Elonva pre-filled syringe information |
|
Manufacturer |
MSD |
Distributor |
Hong Kong: DKSH/Macau: Four Star |
Contents |
Corifollitropin α |
Indications |
Controlled ovarian stimulation (COS) in combination w/ a GnRH antagonist for development of multiple follicles in women on assisted reproductive technology.
Click to view Elonva detailed prescribing infomation |
Dosage |
SC >60 kg 150 mcg single dose, ≤60 kg 100 mcg single dose on stimulation day 1, followed by a GnRH antagonist on day 5 or 6.
Click to view Elonva detailed prescribing infomation |
Overdosage |
View Elonva overdosage for action to be taken in the event of an overdose. |
Contraindications |
Ovarian, breast, uterine, pituitary or hypothalamic tumours. Abnormal vag bleeding. Primary ovarian failure. Ovarian cysts or enlarged ovaries. OHSS. Previous COS cycle resulted in >30 follicles ≥11 mm. Basal antral follicle count >20. Fibroid tumours & reproductive organ malformations.
Click to view Elonva detailed prescribing infomation |
Special Precautions |
Correct hypothyroidism, adrenocortical deficiency, hyperprolactinemia & pituitary or hypothalamic tumours prior treatment. Mild, moderate or severe renal insufficiency. Avoid concomitant GnRH agonist. Polycystic ovarian syndrome. Monitor for potential ovarian hyperresponse. Risk for thromboembolic events. May impair ability to drive or operate machinery. Pregnancy & lactation. Childn.
Click to view Elonva detailed prescribing infomation |
Adverse Drug Reactions |
OHSS, pelvic pain & discomfort, headache, nausea, fatigue, breast tenderness.
View ADR Monitoring Form |
Drug Interactions |
[Click for Elonva detailed prescribing infomation]
View more drug interactions with Elonva |
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Elonva detailed prescribing infomation |
Storage |
View Elonva storage conditions for details to ensure optimal shelf-life. |
Description |
View Elonva description for details of the chemical structure and excipients (inactive components). |
Mechanism of Action |
View Elonva mechanism of action for pharmacodynamics and pharmacokinetics details. |
ATC Classification |
G03GA09 - corifollitropin alfa ; |
Presentation/Packing |
Form |
Packing |
Photo |
Elonva pre-filled syringe |
Elonva 100 mcg/0.5 mL x 1's |
Elonva 150 mcg/0.5 mL x 1's |
|
|
Manufacturer: |
MSD |
Distributor: |
Hong Kong: DKSH
Macau: Four Star |
|
|
|
|
|
|
欧盟批准长效促排卵药Elonva上市
2010年1月28日,默克制药公司宣布欧委会批准Elonva(corifollitropin alfa injection,绒促卵泡素α注射剂),与GnRH(促性腺激素释放激素)拮抗剂联用对患者进行控制性促排卵(COS),它主要用于那些采用辅助生殖技术(ART)生育的妇女,促进其卵泡发育。ELONVA是第一个持续性卵泡刺激剂